GlassScriptPhysician profile
Kimberly A Kick
NPI 1992716377
$2,087.58
in general payments reported to CMS, 2019-2025
28 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.39 · 2020: $40.10 · 2022: $17.33 · 2023: $350 · 2024: $580 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $387.65 | 2019-2025 | |
| Novo Nordisk INC | $247.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $198.90 | 2024-2025 | Farxiga, Bevespi Aerosphere |
| Vanda Pharmaceuticals INC. | $176.73 | 2025 | Fanapt |
| Exact Sciences Corporation | $155.27 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $121.42 | 2024-2025 | Trintellix, Gattex |
| Astellas Pharma US INC | $112.08 | 2024-2025 | Veozah |
| Amgen INC. | $96.55 | 2023-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $57.54 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $56.83 | 2024-2025 | |
| Abbvie INC. | $53.92 | 2023-2024 | |
| Abbott Laboratories | $53.01 | 2024-2025 | Freestyle Libre 3 |
| Corium, LLC | $47.88 | 2025 | Azstarys |
| Lilly USA, LLC | $47.54 | 2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $35.52 | 2023 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.65 | 2023 | Verquvo, Belsomra, Steglatro |
| Daiichi Sankyo INC. | $24.63 | 2025 | Injectafer |
| Ironshore Pharmaceuticals INC. | $22.87 | 2023 | Jornay Pm |
| Biogen, INC. | $19.71 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $18.93 | 2025 | Jornay Pm |
| Inspire Medical Systems, INC. | $18.45 | 2025 | Inspire |
| Cranial Technologies, INC | $16.74 | 2024 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2024 | Trulance, Xifaxan |
| Abiomed | $15.73 | 2025 | |
| Verona Pharma, INC. | $15.37 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $13.55 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $12.51 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Kick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.